Nick Bansback
Overview
Explore the profile of Nick Bansback including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
181
Citations
3917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tam A, Badesha J, Guh D, Bansback N, Peter K, Hollis A, et al.
BioDrugs
. 2025 Feb;
PMID: 39998801
Background: Different biosimilar-promoting policies have been implemented worldwide to improve biosimilar uptake and reduce expenditures on costly biologics. Objective: The aim was to review biosimilar-promoting policies in 13 countries, and...
2.
Waddell L, Mitchener D, Frier K, Jones M, Losina E, Bansback N, et al.
Arthritis Care Res (Hoboken)
. 2025 Feb;
PMID: 39936242
Objective: Posttraumatic osteoarthritis (PTOA) accounts for nearly 12% of osteoarthritis incidences and often occurs after anterior cruciate ligament (ACL) tear. Ensuring the uptake of preventive treatments for PTOA requires that...
3.
Saadat P, Bansback N, Falahee M, Hiligsmann M, Tugwell P, Buchbinder R, et al.
BMJ Open
. 2025 Jan;
15(1):e088267.
PMID: 39819933
Introduction: The pharmacological management of inflammatory arthritis often requires choices that involve trade-offs between benefits, risks and other attributes such as administration route, frequency and cost. This living systematic review...
4.
Hermansen A, Pollard S, McGrail K, Bansback N, Regier D
J Med Internet Res
. 2024 Dec;
26:e63155.
PMID: 39689309
Background: Evaluating precision oncology outcomes requires access to real-world and clinical trial data. Access is based on consent, and consent is based on patients' informed preferences when deciding to share...
5.
Hamoda M, Huynh N, Ayas N, Rompre P, Bansback N, Masse J, et al.
Eur Respir J
. 2024 Dec;
PMID: 39638418
Rationale: Adherence to Continuous Positive Airway Pressure (CPAP) for Obstructive Sleep Apnoea (OSA) continues to be low with high termination rates. Alternative therapies to CPAP are needed. Objectives: To compare...
6.
Roberts E, Bansback N, Tseng C, Shiboski S, Li J, Schmajuk G, et al.
Health Serv Res
. 2024 Dec;
PMID: 39618177
Objective: To analyze the variability in new infliximab biosimilar starts as well as switching from bio-originator to biosimilar infliximab, across insurance payers and rheumatology practices nationally. Study Setting And Design:...
7.
Fatima D, Sweetman A, Lovato N, Vakulin A, Bansback N, Povitz M, et al.
J Clin Sleep Med
. 2024 Oct;
21(3):467-477.
PMID: 39436398
Study Objectives: We aimed to describe similarities and differences in obstructive sleep apnea (OSA) care pathways and their impact on patients in Australia and Canada, including among urban vs rural...
8.
Sadatsafavi M, Khakban A, Mohammadi T, Gupta S, Bansback N
J Clin Epidemiol
. 2024 Sep;
175:111509.
PMID: 39218236
Objectives: A positivity threshold is often applied to markers or predicted risks to guide disease management. These thresholds are often decided exclusively by clinical experts despite being sensitive to the...
9.
Lee J, Barber C, Jung M, Kaminska E, Bansback N, Richards D, et al.
J Rheumatol
. 2024 Aug;
51(11):1077-1083.
PMID: 39147416
Objective: To explore the experiences and perspectives of patients and rheumatologists on decision aid (DA)-led tapering of advanced therapy in rheumatoid arthritis (RA). Methods: Semistructured interviews were completed with patients...
10.
Roberts E, Li J, Bansback N, Tseng C, Shiboski S, Schmajuk G, et al.
Arthritis Rheumatol
. 2024 Jul;
76(12):1739-1742.
PMID: 39077797
Objective: Biosimilars have the potential to reduce spending on biologic drugs, yet uptake has been slower than anticipated. We investigated how successive introductions of infliximab biosimilars influenced their adoption by...